Boletim MB 📩: Who It's For and Who Sponsors It

Covers: Curated summaries of recent clinical trials and medical research across over 35 medical specialties.
For: Doctors, medical residents, researchers, and medical students.
Best for: Healthcare practitioners seeking quick updates on the latest medical studies and treatment protocols.
Skip if: General consumers looking for basic personal health or wellness advice.

Start with

Boletim #40 · Pembrolizumabe sozinho supera a quimio no câncer de endométrio dMMR?: Evaluates clinical trial outcomes of pembrolizumab versus chemotherapy for endometrial cancer.
Boletim #38 · A diálise contínua é mais segura que a intermitente na lesão renal aguda?: Compares safety and outcomes between continuous and intermittent dialysis in acute kidney injury.
Boletim #34 · Trocar HIV oral por injetável a cada 8 semanas melhora o controle viral?: Assesses viral control results when switching HIV patients from oral to injectable treatments.

Summarised by AI from 12 recent issues. Audience size is not included. Prices are not included. Report a mistake.